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Abstract
Background: Osteoarthritis (OA) accounts for one of the most common causes of loss of work and disability
in America. Traditional treatments are aimed at symptomatic relief and maintaining functional capacity, but
have not been shown to modify disease progression. Evidence for inflammatory and immune components in
the development of OA lend support to expanding treatment options to potentially slow the disease and delay
the need for invasive surgical intervention. Hydroxychloroquine (HCQ) is known for its use as an antimalarial
and as a DMARD for rheumatoid arthritis, but has also been considered an option for treatment resistant OA.
Several studies have looked at the medication’s potential for symptomatic relief, and have touched on the
possibility of slowing disease progression in OA, but resources cite the drug as “uncertain benefit” in the realm
of OA treatment. In patients with osteoarthritis, can hydroxychloroquine provide symptomatic improvement?
Method: An exhaustive search using MEDLINE-Ovid, Web of Science, and CINAHL was performed using
keywords: osteoarthritis and hydroxychloroquine. These were screened with eligibility criteria. The resulting
studies were then appraised and assessed for quality with GRADE. Current NIH clinical trials were found to
include two active studies relating to the use of HCQ in OA, with one for hand OA, and the other combining
HCQ and a statin for knee OA.
Results: Three studies were included in this systematic review, meeting the inclusion and exclusion criteria.
One RCT looked at 44 patients with knee OA and showed overall improvement in pain, stiffness, and
function with the treatment of HCQ. A retrospective observational study demonstrated that 6 of 8 patients
with erosive hand OA, on the same dose of HCQ, responded to the treatment with global improvement,
decreased synovitis, and decreased stiffness. Another RCT showed that patients with erosive hand OA had
improvement in joint tenderness, and also saw decreased physiological markers of inflammation and immune
destruction after treatment with HCQ.
Conclusion: Hydroxychloroquine has been shown to provide symptomatic improvement in patients with
OA, both in hand and knee OA, and is a reasonable treatment option for patients resistant to traditional first
line analgesics. To a smaller extent, the drug effect has been assessed on a physiological basis with laboratory
markers, and shown positive results in this respect. Further research into the disease modifying potential and
larger clinical trials are needed in order to further validate this treatment and determine the OA subsets and
patient populations that it would most benefit.
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|| Abstract || 
 
Background: Osteoarthritis (OA) accounts for one of the most common causes of loss of work and disability in 
America. Traditional treatments are aimed at symptomatic relief and maintaining functional capacity, but have not 
been shown to modify disease progression. Evidence for inflammatory and immune components in the development 
of OA lend support to expanding treatment options to potentially slow the disease and delay the need for invasive 
surgical intervention. Hydroxychloroquine (HCQ) is known for its use as an antimalarial and as a DMARD for 
rheumatoid arthritis, but has also been considered an option for treatment resistant OA. Several studies have looked 
at the medication’s potential for symptomatic relief, and have touched on the possibility of slowing disease 
progression in OA, but resources cite the drug as “uncertain benefit” in the realm of OA treatment. In patients with 
osteoarthritis, can hydroxychloroquine provide symptomatic improvement? 
 
Method:  An exhaustive search using MEDLINE-Ovid, Web of Science, and CINAHL was performed using 
keywords: osteoarthritis and hydroxychloroquine. These were screened with eligibility criteria.  The resulting 
studies were then appraised and assessed for quality with GRADE. Current NIH clinical trials were found to include 
two active studies relating to the use of HCQ in OA, with one for hand OA, and the other combining HCQ and a 
statin for knee OA. 
 
Results: Three studies were included in this systematic review, meeting the inclusion and exclusion criteria. One 
RCT looked at 44 patients with knee OA and showed overall improvement in pain, stiffness, and function with the 
treatment of HCQ. A retrospective observational study demonstrated that 6 of 8 patients with erosive hand OA, on 
the same dose of HCQ, responded to the treatment with global improvement, decreased synovitis, and decreased 
stiffness. Another RCT showed that patients with erosive hand OA had improvement in joint tenderness, and also 
saw decreased physiological markers of inflammation and immune destruction after treatment with HCQ. 
 
Conclusion: Hydroxychloroquine has been shown to provide symptomatic improvement in patients with OA, both 
in hand and knee OA, and is a reasonable treatment option for patients resistant to traditional first line analgesics. To 
a smaller extent, the drug effect has been assessed on a physiological basis with laboratory markers, and shown 
positive results in this respect. Further research into the disease modifying potential and larger clinical trials are 
needed in order to further validate this treatment and determine the OA subsets and patient populations that it would 
most benefit. 
 
Keywords: Hydroxychloroquine, osteoarthritis 
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Hydroxychloroquine in the Treatment of Osteoarthritis 
 
BACKGROUND 
Osteoarthritis (OA) is a debilitating condition that accounts for one of the most common 
causes of disability among adults.1 This disease leads to lost productivity via chronic disability 
and affects nearly ¼ of adults over age 18, and 68% of adults over age 65.2 In addition to the 
impact on occupational work, OA stops many patients from doing their favorite athletic 
activities, from sports to simply walking, and even non-athletic everyday activities if it affects 
hands and fingers. Symptomatic control to reduce joint pain and preserve function early on is an 
important role of healthcare providers. 
The theories behind the etiology of OA have changed over the years, which is part of the 
reason new treatment options should be more extensively explored. Classically OA was thought 
to be “non-inflammatory” arthritis, with rheumatoid being the “inflammatory” form, however, 
there is much evidence to support that OA is not simply mechanical wear and tear. The 
pathophysiology showing inflammatory and immune processes behind the chondrocyte 
apoptosis3 leading to the cartilage destruction, “bone-on-bone” narrowed joint space, bone 
edema, and osteophytes seen in OA, lends support to using medications that provide disease 
modification in addition to analgesia. Acetaminophen (APAP) and NSAIDs are the most well-
studied, and first-line interventions in treating OA, but there is very little evidence for slowing of 
disease progression.4 Some NSAIDs, such as diclofenac, have actually been proven to have 
detrimental effects on the disease.5 In addition, many patients fail conservative treatment with 
APAP and NSAIDs, leaving providers with nonsurgical options including pain management on 
opioids or injections with either corticosteroids or viscosupplements. Depending on the patient, 
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these may or may not buy them time until the only option is surgery, which usually involves 
partial or total joint replacement. When considering the pathophysiology behind OA, there are 
less studied interventions that may provide further symptomatic relief, as well as have potential 
for modifying the disease process.  
Among these is hydroxychloroquine (HCQ), a medication well-studied as a DMARD for 
rheumatoid disease and considered to be one of the least toxic of the anti-rheumatics. HCQ not 
only has anti-inflammatory properties, which are thought to be via inhibition of prostaglandin 
production through interference with lysosomal actions; it also has immunomodulatory function. 
This function is thought to be through suppressing interleukin-1’s harmful effect on chondrocyte 
degradation. Nitric oxide is thought to be another culprit in accelerating cartilage degradation, 
and HCQ has been shown to act on chondrocytes to suppress this destructive process. 6 The 
subset of erosive type OA has more evidence to support an immune influence, however, there 
has been increasingly more evidence to show that the disease process of classic OA in large 
joints is also affected by immune-related chondrocyte destruction.  
Hydroxychloroquine itself was originally approved as an antimalarial drug, and is 
currently also used for RA and SLE. Since it is an oral medication that comes in generic form, it 
is cost effective and more easily available than many other immune-modulating drugs and some 
of the more costly NSAIDs such as celecoxib. Side effect profile is also smaller than many other 
anti-rheumatic drugs, with the main concern being potential for chloroquine toxicity in the eye. 
To monitor for this rare side effect, a baseline retina exam is recommended, with a repeat in 5 
years for patients on long-term use of the medication.7 Using HCQ in the treatment of OA is 
currently offlabel, however, there are several completed studies and trials in progress to look at 
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the utility of this medication in treating both the symptoms and disease progression of OA.  Can 
hydroxychloroquine provide symptomatic improvement in patients with osteoarthritis? 
METHODS 
An exhaustive literature search using MEDLINE-Ovid, Web Science, and CINAHL was 
conducted. The following search terms were used: “hydroxychloroquine” and “osteoarthritis.”  
The bibliographies from several relevant background articles were used and inclusion/exclusion 
criteria were applied. Included were studies conducted on patients with osteoarthritis, evaluating 
hydroxychloroquine in comparison to placebo or standard analgesics (including NSAIDs, 
APAP), and measuring symptomatic improvement. Other inclusion criteria required human 
studies and studies published in the English language. Studies were excluded if researchers 
didn’t supply data regarding patient response to therapy. Additionally, conferences or poster 
reports that did not report study details were excluded.  
In a search via NIH for current clinical trials using HCQ for OA, results included one 
recently completed for hand osteoarthritis,8 and a trial that is currently recruiting for combo 
hydroxychloroquine/atorvastatin treatment for knee OA.9 
RESULTS 
The initial search yielded 62 articles for review. After eliminating duplicates and 
screening these results for relevant articles using eligibility criteria, there were a total of 3 
articles. These articles were two randomized controlled trials10,11 and one retrospective 
observational study.12 (See Table 1) Another retrospective observational study was considered, 
but fell under exclusion criteria, since they did not define how they were measuring symptomatic 
improvement of OA in the patients.13 
Jokar et al 
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This was the most recent study10 of the three, performed in 2013, and was a randomized, 
double-blinded, placebo controlled trial. The authors wanted to look at the effect of 
hydroxychloroquine on symptoms of knee osteoarthritis, along with interest in the drug slowing 
progression of OA via its immunomodulatory properties and anti-inflammatory nature. The 
primary outcome evaluated was symptomatic improvement of OA. This was done via the 
WOMAC index, which looked at pain, stiffness, and functional limitation with scoring systems 
for each category.10  
The study enrolled individuals from outpatient clinics who fit criteria designated by 
American College of Rheumatology for knee OA. Exclusion criteria were presence of secondary 
OA or other known inflammatory diseases, knee arthroscopy or corticosteroid injection within 
the past 6 months, hypersensitivity to antimalarials, or eye disease. After meeting criteria, 51 
patients were randomized to either HCQ 200mg or placebo twice daily, and all participants were 
blinded to assignment. Patients were able to use NSAIDS and painkillers that they had already 
been taking, but were asked to keep record and to refrain from taking anything other than the 
study treatment 48 hours before their evaluations.10  
WOMAC scores were recorded at the beginning of the study and at time points over a 
period of 6 months. Loss to follow-up and discontinuation of treatment reduced the study by 7 
patients, leaving a total of 44 patients who were analyzed in the group to which they had been 
initially allocated. Results showed improvement for the treatment group in all three prongs of the 
WOMAC score system, and in using the total WOMAC score of the groups from baseline to day 
180, there was a significant difference between the improvement seen in the treatment group 
compared to the placebo group. The average score went from 124.71 down to 81.14 at day 180 
for the group receiving HCQ, while the placebo group score went from a baseline of 119.70 
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down to 116.48 in the same time period. The authors also noted that the record of pain 
medications used by patients concurrently during the trial showed a smaller number used in the 
HCQ treatment group, at 0.74 pills/day, compared to the placebo group, who reported using 0.96 
pills/day.10  
When interpreting this data, there was not a cutpoint made for the WOMAC score that 
designated individual patients as a “responder” to treatment. Because there is no binary 
“response to the therapy” that would allow an event rate to be calculated with the RR and NNT,14 
the Cohen d index15 may be used to look at the difference in effect size, showing the magnitude 
of effect the treatment had on patients in comparison to the placebo. In looking at the changes in 
WOMAC score from pre to post treatment, the effect magnitude of the HCQ was “large”, as seen 
in Table 1. The authors did not calculate this effect magnitude, but did show the WOMAC scores 
plotted on a graph (Figure 1) demonstrating the treatment group’s significant change in mean 
score over time, and the placebo group’s minimal change from baseline to day 180. In both of 
these representations of data, the results show that there is evidence for symptomatic 
improvement in patients with OA treated with HCQ. The authors do recognize the need for 
larger clinical trials, and that they cannot make any claims about the disease-modifying potential 
of HCQ, since this study only tracked changes in symptoms. With hopes of future confirmation 
that this treatment may slow disease progression, the authors conclude that, at this time, HCQ 
can be considered useful in OA based on the success in symptom reduction seen in this study.10  
Bryant et al 
This was a retrospective observational trial12 looking at similar patients that had received 
the same treatment of hydroxychloroquine over a period of time. The authors wanted to know 
whether HCQ provided the primary outcome of symptomatic relief for patients with erosive 
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subset of osteoarthritis. The authors started with 31 records of patients who met criteria for 
diagnosis of erosive OA, and pared down the group with inclusion criteria to a group of patients 
with complete records, similar baseline characteristics, and same dosage of HCQ (200mg bid) 
over a period of at least 7 months. This resulted in 8 patients who had radiographic changes 
showing OA in their PIP and DIP joints, and who also had complete documentation to review for 
treatment effect.12 
Symptomatic improvement was measured by a three-pronged “overall response,” which 
included evaluation of morning stiffness, synovitis, and patient global assessment. In order to be 
considered a responder to treatment, the patient had to have decreased morning stiffness (50% 
less in duration), resolution of synovitis in at least one joint or reduction of synovitis in at least 
two joints, and improvement of patient global assessment by a point or more. The baseline ESR 
was recorded for all patients, with an average of 20, but a post-treatment value was not taken.12 
Results measured data from the scoring system pre-treatment with HCQ and at 7 mos to 
determine if patients could be classified as a responder to the therapy. In 6 of the 8 patients the 
treatment was considered effective, and they had achieved response meeting the MID (minimum 
important difference) in the evaluation system measuring symptomatic improvement. The other 
two patients also experienced decreased synovitis, but their response did not meet the MID at 7 
months. This anchor-based evaluation determined a 75% response, but without a placebo control, 
the RR or NNT again could not be calculated. This doesn’t translate easily to an effect change on 
the Cohen index, but with the majority of patients meeting the MID, this can be considered a 
“moderate” effect magnitude. The authors concluded that they had confirmed that HCQ “has 
utility in erosive OA,” and recognized that prospective randomized trials are important for 
further validation.12 
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Punzi et al 
This was a randomized placebo-controlled trial,11 and was the only study that looked at 
both symptomatic improvement, as well as physiological markers pre and post treatment with 
HCQ. The patient population in their study had erosive OA and had not responded well to 
traditional analgesics including NSAIDs. Inclusion criteria specified that patients had similar 
radiographic evidence of erosive OA of their PIP and DIP joints, and all individuals were 
screened with exclusion criteria for presence of any other rheumatic diseases.11  
In the study, 15 patients were randomly allocated to receive either HCQ (200mg) or 
traditional analgesics and NSAIDs for 12 months. Measurements were taken at baseline, 6 mos, 
and 12mos, and included a Ritchie index for joint tenderness, and physiological markers 
including ESR and sIL-2R.11  
 Results showed improvement in all three measurements for the treatment group, which 
was to a greater extent than the placebo group. There was no MID determination for treatment 
responder, so the Cohen index was used to look at effect size and magnitude. The Ritchie index 
values decreased from 6.60 to 3.31 in the HCQ group, and from 5.31 to 4.54 in the non-HCQ 
group. This was a “large” effect magnitude when looking at improvement in the treatment group 
compared to the control, as seen in Table 1. Physiological inflammatory marker ESR was 
reduced from 23.01 to 16.17 in patients treated with HCQ, and from 23.62 to 20.34 in the control 
patients. The marker for sIL-2R also had a significant change from 119.67 to 69.23 in the HCQ 
group, compared to the placebo group where the lab value went from 106.78 to 96.42. These two 
markers representing secondary outcome of disease modulation translate to an effect size that is 
of medium-large magnitude on the Cohen index, as seen in Table 1.11  
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The authors concluded that HCQ was efficacious in causing a positive clinical response.  
They note that it is possible that articular changes may be modified by hydroxychloroquine, and 
though further validation is needed, there is a beneficial role for the medication in erosive subsets 
of OA.11  
DISCUSSION 
In synthesizing the results from these three small studies, the consensus was that 
hydroxychloroquine does have utility in providing symptomatic improvement in patients with 
osteoarthritis, more specifically OA involving the knee and the subset of erosive OA involving 
finger joints. There is some evidence for the immunomodulatory capability of HCQ, but its 
utility in the alteration of disease progression needs additional research, ideally with both labs for 
physiological markers and radiographic monitoring. The treatment at dosage of 200mg bid was 
tolerated well, with the only reported ADRs across all three studies being rash in two patients 
and vertigo in one patient.10 There remains a risk of rare choloroquine-induced damage to the 
eye, which would need appropriate monitoring via the baseline ophthalmologic exam and 
additional exam at the 5 year mark in prolonged use.7  As an affordable, easy to take medication, 
HCQ should be kept in mind as an offlabel treatment to use in clinical practice for patients who 
do not respond well to APAP or NSAIDs, and do not wish to move to more invasive 
interventions such as injections or surgery. 
In addition to being a treatment resistant analgesic option, the shift towards altering 
disease progression is an important area of study. Further considerations include novel injectable 
treatments not yet covered by insurance, including platelet-rich plasma (PRP) and stem cell 
therapy (MSC). While acetaminophen and NSAIDs are a good place to start for initial 
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symptomatic control, the prospect of being able to slow disease progression is definitely 
something that is a hopeful prospect for both healthcare providers and patients. 
In appraising the current evidence, some of the issues in variability across studies were 
the specification of erosive/inflammatory arthritis, and the differences in focus on hand joints vs. 
knee joints, however, all patients fell under the category of OA. There was also variability in 
what scale or measurement (i.e. WOMAC, Ritchie index) was used to determine symptomatic 
change, but all clearly addressed whether the joint had become less painful with treatment.  
Other important limitations were the small number of patients in the studies, with the 
largest study being only 44 people. The populations of two of the studies10,12 included only 
women, although they were multiracial and covered an age range from 39-77; the other study11 
did not specify its population characteristics. There was randomization, but not specified 
blinding in the Punzi et al study,11 which was sufficient to downgrade its quality level.  The 
Jokar et al study10 did not have any serious limitations. Looking then at the overall GRADE 
quality16 of the studies, downgrades occurred due to small sample size and unclear blinding.  
Additionally, there is inherent “low” quality of the retrospective observational study in 
comparison to RCTs. These limitations meant that there was an overall “low” quality of evidence 
for the outcome of symptomatic improvement.  Given the single study11 with a very small 
sample size, the quality of evidence was “very low” for the outcome of disease modulation. (See 
Table 1) 
Moving forward from the synthesis of current evidence, clinicians can look to what is 
happening with the use of hydroxychloroquine as treatment in osteoarthritis research today. In 
the search performed for this review, multiple well-designed study protocol outlines were found, 
OA TREAT17 and HERO,18 which looked to better explore the use of HCQ in erosive and non-
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erosive hand OA; however, there was no information on the activity of these studies, other than 
some leads that suggested recruiting was near completion. One study for small joint OA, 
FABIO,8 has a completed status on the NIH site, and a HCQ/statin combination drug is currently 
in progress as a trial for knee OA.9 Aside from these pending findings, a larger RCT for large 
joint OA is definitely needed to follow the positive results of the Jovac et al study;10 more 
importantly, studies looking at physiological markers and radiographic changes are needed to 
establish the connection of HCQ to the disease process of OA. 
CONCLUSION  
Hydroxychloroquine can be considered for treatment of osteoarthritis in patients, and is 
currently used anecdotally for patients who are resistant to initial analgesics such as 
acetaminophen and NSAIDs. Its disease modifying potential, though proven in RA, has not been 
well established for OA. Given the current evidence of low quality, symptomatic relief can be 
seen as a positive primary outcome with HCQ treatment, with minimal evidence for disease 
modulation. Further clinical studies will validate whether hydroxychloroquine does provide both 
symptomatic relief and disease modulation, and will better define the population of patients with 
OA—whether small, large joint, or both—in which HCQ treatment may provide the most 
benefit. 
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TABLE 1  Characteristics of Reviewed Studies, GRADE profile: HCQ as treatment for osteoarthritis
Quality Assessment 
 Downgrade Criteria
No. of 
Studies 
Design Limitations Indirectness Imprecision
Symptomatic improvement 
3 
2 RCT 
1 Retrospect 
Observational 
Blinding 
not 
specified 
(Punzi et 
al11) 
No serious 
indirectness 
Small 
sample 
size 
Disease modulation (via ESR, sIL-2R) 
1 1 RCT 
Blinding 
not 
specified 
(Punzi et 
al11) 
No serious 
indirectness 
Small 
sample 
size 
GRADE: Grading of Recommendations, Assessments, Development and Evaluation.
 
aCohen d index and adjustment for difference in size of placebo/treatment groups, pre/post
bAnchor-based approach with MID (minimum important difference) defined as im
responder; 75% of group were then considered responders, which was not translated to an effect magnitude, but can be consider
cAssessment of change in ESR and effect size, adjusted effect size
dAssessment of change in sIL-2R and effect size, adjusted effect size
 
 
 
FIGURE 1  Changes in WOMAC total score 
 
 
Summary of Findings
  Number of Patients Effect 
 Inconsistency 
Publication 
bias likely 
Study HCQ 
Placebo 
or no 
treatment  
Effect 
Size 
(ES), 
Adjusted 
ESa 
Effect 
Magnitude
No serious 
inconsistencies 
No bias 
likely 
Jokar et 
al10 
21 23 
0.84, 
0.98 
large
Bryant et 
al12 
8 0 
75% 
meet 
MIDb 
medium
Punzi et 
al11 
7 8 
0.70, 
1.07 
large
No serious 
inconsistencies 
No bias 
likely 
Punzi et 
al11 
7 8 
0.70, 
0.60c 
0.63, 
0.87d 
med
 
- treatment evaluation; magnitude determined by Cohen chart
provement of at least one level on patient global assessment score, which determined patient as 
ed a moderate change.
 
 
from baseline (Jovac et al10) 
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Low Important b 
 
-large Very Low Important 
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